Summary

Patients with invasive fungal disease and comorbid conditions such as hematologic malignancy and uncontrolled malignancy were successfully treated with the novel triazole antifungal agent isavuconazole, regardless of minimum inhibitory concentrations required by baseline Aspergillus spp isolates. This article presents data according to type of malignancy from the Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis trial [SECURE; NCT00412893].